pf-06835375
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 17, 2017 (NCT03334851)
Timeline
Indications
Mechanism of action
- C-X-C chemokine receptor type 5INHIBITOR
CXCR5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05070845 | Phase 2 | Nov 15, 2021 | Pfizer |
| NCT03334851 | Phase 1 | Nov 17, 2017 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 2 | 2017 |
1 organizations
Page 1 / 1